Pfizer Can Use German IP Rights to Block Certain EU Imports

Drug companies can rely on patent rights to block some cheaper European Union imports, the bloc’s top court confirmed in a recent decision.

The Court of Justice of the EU (CJEU) ruled Pfizer Inc. can use its patent extension certificate in Germany to halt imports of its Enbrel rheumatoid arthritis drug from EU countries where it was never patented, a provision known as the specific mechanism.

The ruling is a win for Pfizer and other drug companies trying to prevent third parties from importing lower-priced drugs to sell in an EU country where the product costs more.

“The decision confirms ...